Cargando…
The way to precision medicine in gynecologic cancers: The first case report of an exceptional response to alpelisib in a PIK3CA-mutated endometrial cancer
Endometrial cancer (EC) is the most common gynecologic cancer in Europe and its prevalence is increasing. EC includes a biological and clinical heterogeneous group of tumors, usually classified as type I (endometrioid) or type II (non-endometrioid) based on the histopathological characteristics. In...
Autores principales: | Passarelli, Anna, Ventriglia, Jole, Pisano, Carmela, Cecere, Sabrina Chiara, Napoli, Marilena Di, Rossetti, Sabrina, Tambaro, Rosa, Tarotto, Luca, Fiore, Francesco, Farolfi, Alberto, Bartoletti, Michele, Pignata, Sandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880853/ https://www.ncbi.nlm.nih.gov/pubmed/36713525 http://dx.doi.org/10.3389/fonc.2022.1088962 |
Ejemplares similares
-
Targeting immunometabolism mediated by the IDO1 Pathway: A new mechanism of immune resistance in endometrial cancer
por: Passarelli, Anna, et al.
Publicado: (2022) -
Ovarian cancer standard of care: are there real alternatives?
por: Pepa, Chiara Della, et al.
Publicado: (2015) -
Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer
por: Pisano, Carmela, et al.
Publicado: (2013) -
PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives
por: Musacchio, Lucia, et al.
Publicado: (2020) -
Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib
por: Batalini, Felipe, et al.
Publicado: (2020)